Purchase this article with an account.
Rodrigo Bolanos, Sandra Sarmina, Guillermo Dewit, Arturo J Ramirez-Miranda, Enrique O Graue, Alejandro Navas; Photodynamic Therapy With Verteporfin for Corneal Neovascularization. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3246.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To describe the effect of photodynamic therapy (PDT) using verteporfin (Visudyne) on corneal neovascularization (CNV).
Ten eyes of ten patients with corneal neovascularization were treated with a nonthermal laser light at 689 nm delivered 15 minutes after an intravenous infusion of verteporfin. Postoperative outcome of neovascularization was followed clinically (inflammation, intraocular pressure, and visual acuity) and photographically [color photographs and corneal fluorescein and indocyanine green (ICG) angiography] each month for a minimum of 6 months.
Successful photothrombosis of corneal neovascularization was obtained immediately after treatment in the ten patients, and regression was verified by corneal fluorescein and ICG angiography. In five cases, partial vessel recanalization was observed after 6 weeks, and treatment was repeated, with complete regression of new vessels. No relevant side effects were observed in our cases.
PDT with verteporfin could be an effective and safe procedure indicated for patients with corneal neovascularization; however, multiple sessions may be required.
This PDF is available to Subscribers Only